TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).

K Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.